CYT-1853 / Cyteir Therap - LARVOL DELTA

Cyteir Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights (Businesswire) - "2022 Expected Key Milestones...: (i) Present data from Phase 1 CYT-0851 monotherapy dose escalation study; (ii) Announce top line safety data from Phase 1 CYT-0851 combination therapy study; (iii) Announce top line interim results from stage 1 of CYT-0851 Phase 2 monotherapy study; (iv) Design potential registrational trial for one or more indications with CYT-0851; (v) File IND for CYT-1853."

IND • New trial • P1 data • P2 data • Hematological Malignancies • Oncology • Solid Tumor

Cyteir Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights (Businesswire) - P1/2, N=320; NCT03997968; Sponsor: Cyteir Therapeutics, Inc; "Cyteir completed the dose-escalation portion of its Phase 1/2 study of CYT-0851 up to the maximum feasible daily dose of 1200 mg and declared the maximum tolerated dose of 600mg per day. Dose limiting toxicities of fatigue, vomiting, dehydration, dry skin, stomatitis, myalgia, and acidosis were observed at daily doses of 600mg and above...We continue to enroll patients at the 400mg per day dose....we are initiating Phase 2 expansion study into disease-specific cohorts and expect to begin enrolling patients in the first quarter of 2022. We are also initiating a Phase 1 combination study of CYT-0851 with three standard-of-care regimens: rituximab plus bendamustine, gemcitabine and capecitabine, in both hematologic malignancies and solid tumors; Investigational New Drug (IND)-enabling studies with CYT-1853 are ongoing and the Company expects to submit an IND application for CYT-1853 in 2022."

Enrollment status • IND • New P1 trial • New P2 trial • P1/2 data • Breast Cancer • Gynecologic Cancers • Head and Neck Cancer • Hematological Malignancies • Leukemia • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Triple Negative Breast Cancer

Cyteir Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights (Businesswire) - "Second Quarter Business Review and Operational Updates: CYT-0851 - The Phase 1 dose escalation trial portion of the Phase 1/2 trial continues to enroll patients. The 600 mg once daily cohort was recently cleared for safety and the 800 mg once daily cohort is now open for enrollment. Initiation of the Phase 2 expansion trial and Phase 1 combinations with chemotherapy are both expected by year-end...Investigational New Drug (IND)-enabling studies with CYT-1853 are ongoing and an IND application is expected to be submitted in 2022."

IND • Trial status • Hematological Malignancies • Oncology • Solid Tumor